Literature DB >> 30191033

Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma.

Francesco Tovoli1, Giulia Negrini1, Luigi Bolondi1.   

Abstract

Hepatocellular carcinoma is one of the most common malignancies and represents a unique challenge for physicians and patients. Treatment patterns are not uniform between areas despite efforts to promote a common protocol. Even if most hepatologists worldwide adopt the Barcelona Clinic Liver Cancer staging system, Asian and North American physicians are also independently making an effort to expand the indications of each treatment, combining therapies for better outcomes. Also, new therapeutic techniques have emerged and an increasing number of studies are trying to include these paradigm shifts into newer treatment guidelines. Controversial and diverging points in the current international guidelines are emphasized and discussed. Unanswered questions are also analyzed to identify the most needed and promising future perspectives.

Entities:  

Keywords:  chemoembolization; hepatocellular carcinoma; thermal ablation

Year:  2016        PMID: 30191033      PMCID: PMC6095419          DOI: 10.2217/hep-2015-0006

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN: 2045-0923


  98 in total

1.  Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

Authors:  Bruno Sangro; Livio Carpanese; Roberto Cianni; Rita Golfieri; Daniele Gasparini; Samer Ezziddin; Philipp M Paprottka; Francesco Fiore; Mark Van Buskirk; Jose Ignacio Bilbao; Giuseppe Maria Ettorre; Rita Salvatori; Emanuela Giampalma; Onelio Geatti; Kai Wilhelm; Ralf Thorsten Hoffmann; Francesco Izzo; Mercedes Iñarrairaegui; Carlo Ludovico Maini; Carlo Urigo; Alberta Cappelli; Alessandro Vit; Hojjat Ahmadzadehfar; Tobias Franz Jakobs; Secondo Lastoria
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

2.  Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.

Authors:  Wen-Yen Huang; Yee-Min Jen; Meei-Shyuan Lee; Li-Ping Chang; Chang-Ming Chen; Kai-Hsiung Ko; Kuen-Tze Lin; Jang-Chun Lin; Hsing-Lung Chao; Chun-Shu Lin; Yu-Fu Su; Chao-Yueh Fan; Yao-Wen Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-17       Impact factor: 7.038

3.  Is contrast-enhanced US alternative to spiral CT in the assessment of treatment outcome of radiofrequency ablation in hepatocellular carcinoma?

Authors:  P Ricci; V Cantisani; F Drudi; E Pagliara; M Bezzi; F Meloni; F Calliada; S M Erturk; V D'Andrea; U D'Ambrosio; R Passariello
Journal:  Ultraschall Med       Date:  2009-03-11       Impact factor: 6.548

4.  Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.

Authors:  Laura M Kulik; Brian I Carr; Mary F Mulcahy; Robert J Lewandowski; Bassel Atassi; Robert K Ryu; Kent T Sato; Al Benson; Albert A Nemcek; Vanessa L Gates; Michael Abecassis; Reed A Omary; Riad Salem
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

Review 5.  Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

Authors:  Calogero Cammà; Filippo Schepis; Ambrogio Orlando; Maddalena Albanese; Lillian Shahied; Franco Trevisani; Pietro Andreone; Antonio Craxì; Mario Cottone
Journal:  Radiology       Date:  2002-07       Impact factor: 11.105

6.  Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.

Authors:  Takeaki Ishizawa; Kiyoshi Hasegawa; Taku Aoki; Michiro Takahashi; Yosuke Inoue; Keiji Sano; Hiroshi Imamura; Yasuhiko Sugawara; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

Review 7.  Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies.

Authors:  Yun Ku Cho; Jae Kyun Kim; Mi Young Kim; Hyunchul Rhim; Joon Koo Han
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

Review 8.  Hepatocellular carcinoma: clinical frontiers and perspectives.

Authors:  Jordi Bruix; Gregory J Gores; Vincenzo Mazzaferro
Journal:  Gut       Date:  2014-02-14       Impact factor: 23.059

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis.

Authors:  Alessandro Federico; Michele Orditura; Gaetano Cotticelli; Ilario DE Sio; Marco Romano; Antonietta Gerarda Gravina; Marcello Dallio; Alessio Fabozzi; Fortunato Ciardiello; Carmela Loguercio; Ferdinando DE Vita
Journal:  Oncol Lett       Date:  2015-02-12       Impact factor: 2.967

View more
  5 in total

1.  Cholangiocarcinoma: from risk to prevention?

Authors:  Giovanni Brandi; Stefania De Lorenzo; Francesco Tovoli
Journal:  Transl Gastroenterol Hepatol       Date:  2016-06-24

Review 2.  Comparison of the current international guidelines on the management of HCC.

Authors:  Friedrich Foerster; Peter Robert Galle
Journal:  JHEP Rep       Date:  2019-05-28

3.  Non-SMC Condensin I Complex, Subunit G (NCAPG) is a Novel Mitotic Gene Required for Hepatocellular Cancer Cell Proliferation and Migration.

Authors:  Qun Zhang; Ruixia Su; Chun Shan; Chao Gao; Pei Wu
Journal:  Oncol Res       Date:  2017-10-18       Impact factor: 5.574

Review 4.  Systemic treatments for hepatocellular carcinoma: challenges and future perspectives.

Authors:  Francesco Tovoli; Giulia Negrini; Francesca Benevento; Chiara Faggiano; Elisabetta Goio; Alessandro Granito
Journal:  Hepat Oncol       Date:  2018-02-08

5.  Hot topics in hepatocellular carcinoma.

Authors:  Luca Ielasi; Elisabetta Goio; Francesco Tovoli
Journal:  Transl Cancer Res       Date:  2019-04       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.